Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 + Anlotinib in Advanced Biliary Adenocarcinoma/HCC
NCT03825705Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2019
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart in biliary adenocarcinoma, hepatocellular carcinoma (HCC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Status: unknown.
02
Drugs
benmelstobart
03
Conditions
biliary adenocarcinomahepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03825705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03825705.